200 related articles for article (PubMed ID: 24608079)
1. Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group.
Tower RL; Jones TL; Camitta BM; Asselin BL; Bell BA; Chauvenet A; Devidas M; Halperin EC; Pullen J; Shuster JJ; Winick N; Kurtzberg J
J Pediatr Hematol Oncol; 2014 Jul; 36(5):353-61. PubMed ID: 24608079
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study.
Krance RA; Newman EM; Ravindranath Y; Harris MB; Brecher M; Wimmer R; Shuster JJ; Land VJ; Pullen J; Crist W
Cancer; 1991 Feb; 67(3):550-6. PubMed ID: 1985748
[TBL] [Abstract][Full Text] [Related]
3. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
4. Intensive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: A Pediatric Oncology Group Pilot Study.
Lauer SJ; Camitta BM; Leventhal BG; Mahoney D; Shuster JJ; Kiefer G; Pullen J; Steuber CP; Carroll AJ; Kamen B
J Pediatr Hematol Oncol; 1998; 20(3):229-33. PubMed ID: 9628434
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group.
Salzer WL; Devidas M; Carroll WL; Winick N; Pullen J; Hunger SP; Camitta BA
Leukemia; 2010 Feb; 24(2):355-70. PubMed ID: 20016527
[TBL] [Abstract][Full Text] [Related]
6. Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Ochs J; Rivera GK; Pollock BH; Buchanan G; Crist W; Freeman AI
Cancer; 1990 Oct; 66(8):1671-7. PubMed ID: 2208021
[TBL] [Abstract][Full Text] [Related]
7. Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Lauer SJ; Camitta BM; Leventhal BG; Mahoney DH; Shuster JJ; Adair S; Casper JT; Civin CI; Graham M; Kiefer G
Cancer; 1993 May; 71(9):2854-61. PubMed ID: 8467463
[TBL] [Abstract][Full Text] [Related]
8. Acute lymphoblastic leukemia in a developing country: preliminary results of a nonrandomized clinical trial in El Salvador.
Bonilla M; Moreno N; Marina N; deReyes G; Shurtleff SA; Downing JR; Behm FG; Harrison PL; Ribeiro RC; Peña O; Crist WM; Antillon FG
J Pediatr Hematol Oncol; 2000; 22(6):495-501. PubMed ID: 11132215
[TBL] [Abstract][Full Text] [Related]
9. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial.
Lauer SJ; Shuster JJ; Mahoney DH; Winick N; Toledano S; Munoz L; Kiefer G; Pullen JD; Steuber CP; Camitta BM
Leukemia; 2001 Jul; 15(7):1038-45. PubMed ID: 11455971
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy for initial induction failures in childhood acute lymphoblastic leukemia: a Children's Oncology Group Study (POG 8764).
Joyce MJ; Pollock BH; Devidas M; Buchanan GR; Camitta B
J Pediatr Hematol Oncol; 2013 Jan; 35(1):32-5. PubMed ID: 23211688
[TBL] [Abstract][Full Text] [Related]
11. Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.
Estlin EJ; Yule SM; Lowis SP
Cancer Treat Rev; 2001 Dec; 27(6):339-50. PubMed ID: 11908927
[TBL] [Abstract][Full Text] [Related]
12. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study.
Petersdorf SH; Kopecky KJ; Head DR; Boldt DH; Balcerzak SP; Wun T; Roy V; Veith RW; Appelbaum FR
Leukemia; 2001 Feb; 15(2):208-16. PubMed ID: 11236936
[TBL] [Abstract][Full Text] [Related]
14. Improved treatment results in boys with overt testicular relapse during or shortly after initial therapy for acute lymphoblastic leukemia. A Pediatric Oncology group study.
Buchanan GR; Boyett JM; Pollock BH; Smith SD; Yanofsky RA; Ghim T; Wharam MD; Crist WM; Vietti TJ; Johnson W
Cancer; 1991 Jul; 68(1):48-55. PubMed ID: 2049752
[TBL] [Abstract][Full Text] [Related]
15. No impact of high-dose cytarabine and asparaginase as early intensification with intermediate-risk paediatric acute lymphoblastic leukaemia: results of randomized trial TCCSG study L99-15.
Kato M; Koh K; Manabe A; Saito T; Hasegawa D; Isoyama K; Kinoshita A; Maeda M; Okimoto Y; Kajiwara M; Kaneko T; Sugita K; Kikuchi A; Tsuchida M; Ohara A
Br J Haematol; 2014 Feb; 164(3):376-83. PubMed ID: 24164537
[TBL] [Abstract][Full Text] [Related]
16. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group.
Crist W; Shuster J; Look T; Borowitz M; Behm F; Bowman P; Frankel L; Pullen J; Krance R; Steuber P
Leukemia; 1992; 6 Suppl 2():162-6. PubMed ID: 1578922
[TBL] [Abstract][Full Text] [Related]
17. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
[TBL] [Abstract][Full Text] [Related]
18. Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report.
Laver JH; Barredo JC; Amylon M; Schwenn M; Kurtzberg J; Camitta BM; Pullen J; Link MP; Borowitz M; Ravindranath Y; Murphy SB; Shuster J
Leukemia; 2000 Mar; 14(3):369-73. PubMed ID: 10720128
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia.
Rivera GK; Hudson MM; Liu Q; Benaim E; Ribeiro RC; Crist WM; Pui CH
Blood; 1996 Aug; 88(3):831-7. PubMed ID: 8704238
[TBL] [Abstract][Full Text] [Related]
20. Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect.
Chiu EK; Chan LC; Liang R; Lie A; Kwong YL; Todd D; Chan TK
Leukemia; 1994 Sep; 8(9):1469-73. PubMed ID: 8090027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]